Sudeep Pharma Limited Link 
Allotment
Sudeep Pharma IPO is a book-built issue that opened on November 21, 2025, and closed on November 25, 2025. The company plans to raise approximately ₹895 crore through the IPO, comprising a fresh issue of ₹95.00 crore and an offer for sale of up to 13,490,726 equity shares, each with a face value of ₹1.
The price band for the IPO is set at ₹563 to ₹593 per share. The issue allocation is structured with 35% reserved for retail investors, 50% for Qualified Institutional Buyers (QIBs), and 15% for High Net-worth Individuals (HNIs).
The allotment for the Sudeep Pharma IPO is scheduled for November 26, 2025, and the shares are proposed to be listed on both the BSE and NSE on November 28, 2025.
Financial Highlights
Revenue: ₹511.33 crore in FY2025, compared to ₹465.38 crore in FY2024
Profit: ₹138.69 crore in FY2025, up from ₹133.15 crore in FY2024
Based on the company’s strong and consistent financial performance, Sudeep Pharma IPO may be considered for long-term investment.
₹593
0%
Open
₹593
HIgh - Low
₹593
Previous Close
₹593
Total Traded Value
0
52 Weeks High
₹593
52 Weeks Low
₹593
Updates On
Nov 10, 2025
IPO. Open
Nov 21, 2026
IPO. Close
Nov 25, 2026
IPO. Price
₹593.00
IPO Market price
₹6,697.85 Cr
IPO Details
| IPO Date | 28 Nov |
| IPO Listing Date | 28 Nov |
| IPO Face Value | ₹1.00 per share |
| IPO Price Range | ₹593.00 |
| IPO Issue Size | 1,50,92,749 shares |
| IPO Sale Type | Fresh Capital & OFS |
| Employee Discount | - |
| IPO Issue Type | Bookbuilding IPO |
| IPO Listing | BSE, NSE Platform |
| Share Holding Pre Issue | 11,13,46,602 shares |
IPO Timeline
| IPO Open Date | 21 Nov |
| IPO Close Date | 25 Nov |
| IPO Allotment (Tentative) | 26 Nov |
| Refunds | 27 Nov |
| Credit to Demat Account | 27 Nov |
| IPO Listing Date | 28 Nov |
IPO Reservation
| Category | Offer |
|---|---|
| QIB Shares Offered | 75,46,373 |
| NII (HNI) Shares Offered | 22,63,913 |
| Retail Shares Offered | 52,82,463 |
IPO Lot Size
Investors can bid for a minimum of 25 shares, with additional shares in multiples of 25.
| Application | Lots | Share | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 35 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹1,92,725 |
| S-HNI (Min) | 14 | 350 | ₹2,07,550 |
| S-HNI (Max) | 67 | 1,675 | ₹9,93,275 |
| B-HNI (Min) | 68 | 1,700 | ₹10,08,100 |
Incorporated in 1989, Sudeep Pharma Limited is engaged in the manufacturing of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, serving customers in over 100 countries worldwide.
The company operates six manufacturing facilities with a combined production capacity of approximately 50,000 metric tonnes per annum (MTPA). Its manufacturing capabilities cover a wide range of minerals, including calcium, iron, magnesium, zinc, potassium, and sodium.
Sudeep Pharma supplies over 200 products to a diversified customer base across the pharmaceutical, food, and nutrition industries. The company is supported by strong in-house research and development capabilities, including laboratories and pilot-scale facilities focused on the development of mineral salts and excipients.
Product Portfolio
Pharmaceutical, Food, and Nutrition Ingredients
Specialty Ingredients
Triturates
As of December 31, 2024, the company employed 704 permanent employees.
Competitive Strengths
Market leadership with a diversified product portfolio in a high entry-barrier industry
Strong global customer base with long-standing relationships
Well-equipped and regulatory-compliant manufacturing facilities
Robust research and development capabilities
Company Financials (Consolidated)
| Assets | 922.26 | 717.17 | 513.87 |
| Total Income | 130.08 | 511.33 | 465.38 |
| Profit After Tax | 31.27 | 138.69 | 133.15 |
| EBITDA | 48.57 | 199.28 | 187.76 |
| NET Worth | 688.32 | 497.53 | 359.07 |
| Reserves and Surplus | 668.52 | 481.11 | 354.59 |
| Total Borrowing | 135.97 | 135.25 | 75.03 |
Key Performance Indicator (KPI)
| ROE | - |
| ROCE | - |
| Debt/Equity | 0.2 |
| RoNW | 27.88% |
| PAT Margin | 27.63% |
| EBITDA Margin | 39.70% |
| Price to Book Value | 12.93 |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | - |
| 2 | To meet out the expenses of Working Capital Requirement | - |
| 3 | To meet out the General Corporate Purposes; | 12.67 |
| 4 | Offer for Sale (OFS) | - |
Contact Details
Sudeep Pharma Ltd.
129/1/A,
GIDC Estate,
Nandesari,
Vadodara, Gujarat, 391340
Phone: +91 265 284 0656
Email: cs.sudeep@sudeepgroup.com
Website: https://www.sudeeppharma.com/
Detail Registrar
IPO Registrar
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: sudeeppharma.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
The Sudeep Pharma IPO opened on November 21, 2025, and closed on November 25, 2025. Allotment was scheduled for November 26, and listing on BSE & NSE on November 28, 2025.
The IPO price band was ₹563–₹593 per share, with a lot size of 25 shares. Retail investors could apply for a minimum of 25 shares and in multiples of 25 shares thereafter.
Proceeds were allocated for capital expenditure on machinery at the Nandesari production facility and for general corporate purposes, supporting the company’s expansion and operational needs.
Sudeep Pharma manufactures pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, serving pharmaceutical, food, and nutrition industries with over 200 products globally.
Revenue grew 10% to ₹511.33 crore in FY2025 from ₹465.38 crore in FY2024, while PAT rose 4% to ₹138.69 crore, indicating steady growth and operational efficiency.
Compare:
